𝔖 Bobbio Scriptorium

✦ LIBER ✦

Silent coronary artery disease in diabetes – a feature of autonomic neuropathy or accelerated atherosclerosis?

✍ Scribed by K. E. J. Airaksinen

Publisher: Springer
Year: 2001
Tongue: English
Weight: 82 KB
Volume: 44
Category: Article
ISSN: 0012-186X
DOI: 10.1007/s001250051609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiac autonomic neuropathy in patients

Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability

✍ Arthur J. H. A. Scholte; Joanne D. Schuijf; Victoria Delgado; Jurriaan A. Kok; M 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 193 KB

The risk of developing coronary artery d

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

✍ Kevin M. Pantalone; Michael W. Kattan; Changhong Yu; Brian J. Wells; Susana Arri 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 286 KB

Pantalone et al.: The risk of developing

Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

✍ David S. H. Bell 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 75 KB

Retinol-binding protein 4 is associated

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

✍ M. von Eynatten; P. M. Lepper; D. Liu; K. Lang; M. Baumann; P. P. Nawroth; A. Bi 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 337 KB

Letter to the Editor re: the Letter to t

Letter to the Editor re: the Letter to the Editor by Dr. David Samuel Henry Bell, MD regarding “The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis”

✍ Robert S. Zimmerman; Kevin Matthew Pantalone 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 82 KB